financetom
Business
financetom
/
Business
/
CIBC Comments on Canada October Retail Sales, November's Advance Estimate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CIBC Comments on Canada October Retail Sales, November's Advance Estimate
Dec 20, 2024 6:08 AM

08:48 AM EST, 12/20/2024 (MT Newswires) -- Canadian retail sales Friday posted a second consecutive 0.6% month-over-month advance in October, although the details weren't as strong as in the prior month, said CIBC.

Much of the gain in October sales was driven by prices and by increased spending in the often volatile auto sector, noted the bank. Excluding auto, sales rose by a more muted 0.1% month over month following an upwardly revised 1.1% surge in the prior month)+, while total sales were flat in volume terms.

Gains in furniture & electronic stores were offset by declines in building materials & supplies and food & beverage.

The advance estimate for November pointed to no change in sales relative to the prior month. However, the announcement by the federal government in late November of a GST holiday beginning mid-December may have encouraged some households to defer purchases and as such could have dampened November retail sales slightly, stated CIBC.

The bank will need to see the December data to get a full view of holiday spending.

Even though the latest release wasn't as strong as the prior one, consumer spending has still clearly improved relative to the trend seen earlier in the year, added CIBC. However, that fact is to be welcomed and not feared from an inflation point of view.

Evidence of bloated inventory levels in the retail sector during the first half of the year showed plenty of room for spending to accelerate without necessarily resulting in upward pressure on prices., according to the bank

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Platinum Analytics Cayman Shares Jump in Nasdaq Debut
Update: Platinum Analytics Cayman Shares Jump in Nasdaq Debut
Sep 21, 2025
01:16 PM EDT, 09/19/2025 (MT Newswires) -- (Updates with recent share movement in the first and second paragraphs.) Platinum Analytics Cayman (PLTS) shares were up more than 46% in recent trading after the company's stock made its debut on Nasdaq earlier Friday following an initial public offering of 2 million shares that were priced at $4 each for $8 million...
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Sep 21, 2025
By Puyaan Singh Sept 19 (Reuters) - Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial. The bispecific antibody therapy, Lynozyfic, showed a 100% overall response rate in a study with 24 patients with high-risk smoldering multiple myeloma. The...
Red Cat Closes $172.5 Million Public Offering
Red Cat Closes $172.5 Million Public Offering
Sep 21, 2025
01:17 PM EDT, 09/19/2025 (MT Newswires) -- Red Cat Holdings ( RCAT ) said Friday that it has closed an underwritten public offering of about 18 million common shares, which includes 2.34 million shares from the underwriters' option, for gross proceeds of $172.5 million. The company intends to use the proceeds for general corporate purposes and working capital, including funding...
EMA Backs Amgen Drug For Rare Autoimmune Disorder
EMA Backs Amgen Drug For Rare Autoimmune Disorder
Sep 21, 2025
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a rare, chronic, autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammation in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved